Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Investigation of Durability of Sars-Cov-2-Specific Igg and Igm Antibodies in Recovered Covid-19 Patients: A Prospective Study Publisher



Zamani M1 ; Ghasemi A2 ; Shamshirgaran M2 ; Ahmadpour S3 ; Hormati A4 ; Khodadadi J5 ; Varnasseri M6 ; Amini F7 ; Shayanrad A8 ; Younesi V9 ; Poustchi H8 ; Shabani M10
Authors

Source: Avicenna Journal of Medical Biotechnology Published:2022


Abstract

Background: Evidence on seroconversion profile of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients is limited. We mainly aimed to evaluate seroconversion and persistence of virus-specific antibodies in patients infected by coronavirus disease 2019 (COVID-19). Methods: This prospective study was conducted on 118 patients with COVID-19 presen-tations admitted to three hospitals in Iran and recovered from the disease, during April and May 2020. Presence of COVID-19 was confirmed by Polymerase Chain Reaction (PCR) testing on nasopharyngeal swabs. Serum samples were collected at different time points, including 0-5, 6-15, 16-25, 26-35, and 36-95 days of clinical symptom onset. For measurement of SARS-CoV-2-specific IgG and IgM antibody titers, Iran's Food and Drug Administration-approved SARS-CoV-2 ELISA kits were used. Results: Serologic assay revealed that 37.3% of patients (n=44) were positive for IgM at 0-5 days interval after clinical symptom onset. This rate was 60.2% (n=71) for IgG. There were increasing IgM and IgG seroconversion rates during first 25 days of clinical symptom onset, but seropositivity started to decrease thereafter, which was more evi-dent for IgM (17.9%) than IgG (58.9%) at the 36-95 days post symptoms appearance. In other words, it was found that 83.6% of IgM-positive and 32.9% of IgG-positive patients in the first month of clinical symptom onset became seronegative in the third month of clinical symptom onset. Conclusion: The findings demonstrated that antibody responses to SARS-CoV-2 infection were developed in recovered COVID-19 patients; however, some of them were seronegative three months after onset of relevant symptoms. Furthermore, the stability of anti-SARS-CoV-2 antibodies could also correct our expectations from COVID-19 vaccination responses. © 2022, Avicenna Journal of Medical Biotechnology. All rights reserved.
Other Related Docs
8. Covid-19: Significance of Antibodies, Human Antibodies (2020)
10. The Immunologic Basis of Covid-19: A Clinical Approach, Journal of Cellular and Molecular Anesthesia (2020)
12. Serological and Molecular Tests for Covid-19: A Recent Update, Iranian Journal of Immunology (2021)
13. Ten Challenging Questions About Sars-Cov-2 and Covid-19, Expert Review of Respiratory Medicine (2020)
14. Soluble Ace2 As a Risk or Prognostic Factor in Covid-19 Patients: A Cross-Sectional Study, Medical Journal of the Islamic Republic of Iran (2022)
16. Antibody Formation As an Immune Response in Patients Infected With Sars Covid-19, African Journal of Biological Sciences (South Africa) (2024)
19. Pharmacological Treatments of Covid-19, Pharmacological Reports (2020)